ArticleCell death and differentiation2019
Constitutive IP
Article in Cell death and differentiation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 81 citations in OpenAlex.
- Cryo-EM insights into isoform-specific properties of the IPNature communications · 2026Article
- Mitochondria-ER crosstalk via MAMS: Bridging cellular homeostasis and cancer progression.Apoptosis : an international journal on programmed cell death · 2026Review
- Review
- Store-operated calcium entry facilitates LPS-induced superoxide anion-dependent macrophage extracellular traps.Open biology · 2025Article
- The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.Journal of cancer research and clinical oncology · 2024Article
- IP3R2-mediated CaCell death discovery · 2024Article
- The Complex Effects of PKM2 and PKM2:IPCells · 2023Article
- Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells.Cell death & disease · 2023Article
- Sustained IP3-linked CaFrontiers in cell and developmental biology · 2023Article
- Platelet-Derived Extracellular Vesicles Stimulate Migration through Partial Remodelling of the CaCells · 2022Article
- Bcl-xL acts as an inhibitor of IPCell death and differentiation · 2022Article
- Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.Frontiers in oncology · 2022Review
- Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.Exploration of targeted anti-tumor therapy · 2022Article
- SIRT3 protects bovine mammary epithelial cells from heat stress damage by activating the AMPK signaling pathway.Cell death discovery · 2021Article
- Dynamic control of mitochondria-associated membranes by kinases and phosphatases in health and disease.Cellular and molecular life sciences : CMLS · 2021Review
- Balancing ER-Mitochondrial CaTrends in cell biology · 2021Review
- Mitochondrial CaCells · 2021Review
- IPProgress in molecular and subcellular biology · 2021Review
- In the Right Place at the Right Time: Regulation of Cell Metabolism by IP3R-Mediated Inter-Organelle CaFrontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5-trisphosphate (IP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.